SFI
VRCA icon

Susquehanna Fundamental Investments’s Verrica Pharmaceuticals VRCA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,800
Closed -$182K – 884
2023
Q1 		$182K Hold
2,800
– – ﹤0.01% 872
2022
Q4 		$77K Hold
2,800
– – ﹤0.01% 1129
2022
Q3 		$82K Buy
+2,800
New +$95.9K ﹤0.01% 1351

Other funds holding VRCA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna Fundamental Investments's VRCA Position: Q2 2023 in Review

Susquehanna Fundamental Investments sold out of Verrica Pharmaceuticals (VRCA) in Q2 2023, closing a stake of 2,800 shares — an estimated $182K sold.

Susquehanna Fundamental Investments first reported a position in VRCA in Q3 2022 and held it in 3 quarters. The position peaked at $182K in Q1 2023. 63 funds tracked by Wall St. Rank hold VRCA as of Q2 2023.

  • Susquehanna Fundamental Investments reported no remaining Verrica Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 2,800 Verrica Pharmaceuticals shares in Q2 2023, an estimated $182K.
  • Susquehanna Fundamental Investments first reported a position in Verrica Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's Verrica Pharmaceuticals position peaked at $182K in Q1 2023.
  • 63 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2023, filed 11 Aug 2023.